

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
01 July 2021 (01.07.2021)



(10) International Publication Number
WO 2021/133776 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) A61P 11/06 (2006.01)

(21) International Application Number:
PCT/US2020/066559

(22) International Filing Date:
22 December 2020 (22.12.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/952,996 23 December 2019 (23.12.2019) US
62/964,970 23 January 2020 (23.01.2020) US

(71) Applicants: **SANOFI BIOTECHNOLOGY** [FR/FR]; 54 rue La Boétie, 75008 Paris (FR). **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(72) Inventors: **GOULAOUIC, Helene**; c/o SANOFI BIOTECHNOLOGY, 54 rue La Boétie, 75008 Paris (FR). **HADDAD, El-Bdaoui**; c/o SANOFI, 55 Corporate Drive, Mail Stop 55A-525, Bridgewater, New Jersey 08807 (US). **HAMON, Sara**; c/o REGENERON PHARMACEUTICALS, INC., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **HAREL, Sivan**; c/o REGENERON PHARMACEUTICALS, INC., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **KALLIOLIAS, Georgios**; c/o REGENERON PHARMACEUTICALS, INC., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **RUDDY, Marcella**; c/o REGENERON PHARMACEUTICALS, INC., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US).

(74) Agent: **STONE-HULSLANDER, Judith**; Lathrop GPM LLP, 28 State Street, Boston, Massachusetts 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: METHODS FOR TREATING OR PREVENTING ALLERGIC ASTHMA BY ADMINISTERING AN IL-33 ANTAGONIST AND/OR AN IL-4R ANTAGONIST

(57) Abstract: Methods for treating or preventing allergic asthma and associated conditions in a subject are provided. Certain methods disclosed here comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-33 (IL-33) antagonist, such as an anti-IL-33 antibody. Other methods disclosed here comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4R (IL-4R) antagonist, such as an anti-IL-4R antibody. Still other methods disclosed here comprise administering to a subject in need thereof a first therapeutic composition comprising an interleukin-33 (IL-33) antagonist, such as an anti-IL-33 antibody, and a second therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody. Allergic asthma-associated signature genes are provided. Methods of altering (e.g., decreasing) an expression level of one or more allergic asthma-associated signature genes in a subject having allergic asthma are provided.



WO 2021/133776 A1